ESMO 2024 – Bristol heads for phase 3 in small-cell
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
It’s back to school for biotech, with a packed conference schedule.
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.